Please login to the form below

Not currently logged in
Email:
Password:

OPKO appoints vice president of medical affairs

Dr Douglass Laidlaw brings experience from Relypsa and Sanofi

OPKO Health Dr Douglass LaidlawMiami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs.

In his new role, Dr Laidlaw will be particularly responsible for overseeing the anticipated launch of the healthcare company's product Rayaldee.

Dr Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, which include Genzyme, Keryx, Neurocine Biosciences and Serono.

He previously served as Relypsa's executive director, medical affairs and Sanofi's national director for medical science liasons, medical affairs.

Philip Frost, chairman and chief executive of OPKO, said: “Doug is a key addition to the management team in OPKO's renal division.

“A well-conceived and executed medical education strategy is critical to Rayaldee's acceptance by US healthcare professionals.”

6th June 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...